Diligence memo · auto-generated · as of July 2, 2026

Ascend Advanced Therapies Group, Inc.

Ascend Advanced Therapies Group, Inc. looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Ascend Advanced Therapies Group, Inc. operates in Other, based in ALACHUA.

Sector still resolves to a broad 'Other' bucket, so operating comparables below are weaker than for a tightly-classified peer.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ascend Advanced Therapies Group, Inc. has raised $131M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $131M on 2024-11-06.

Most recent recorded round closed around 2024-11-06.

Valuation (modeled)modeled

Provath models Ascend Advanced Therapies Group, Inc. at approximately $1.2B (range $740M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.87× the median modeled value of Series D+ Other companies in 2022–2024 (109 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 20 mo ago; this sector typically re-raises about every 11 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 97% of Other peers (25015 compared).

Modeled value ranks above 97% of those peers.

Closest niche peers: Getaround, Inc, Relentless Topco, Inc., NQ PE Project Colosseum Parent, L.P., Cowboy Topco, Inc., Office Topco, Llc.

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Broad sector classification weakens peer comparison.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.